BRAF and melanoma: In light of the added toxicity of the triple agent approach and the lack of mature data that demonstrate the OS benefit of the triple therapy, guidelines are yet to outline the exact role of this regimen in treating BRAF-positive melanoma and the implications it has on the currently available dual agent options [42].